Velcade shown effective against Mantle Cell Lymphoma

Well, it was nearly 2 years ago when I first wrote about new trials of Velcade® (bortezomib) for treating Mantle Cell Lymphoma, a stubborn form of NHL that has resisted treatment for many patients.

According to an article published in the Journal of Clinical Oncology [Kahl B, Bernstein S, Fisher R. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractive Mantle Cell Lymphoma. Journal of Clinical Oncology. 2006;24:4867-4874], Velcade is an effective treatment option for patients with mantle cell lymphoma that has stopped responding to prior therapies.

Researchers from several medical institutions in the US recently conducted a clinical trial to evaluate Velcade in the treatment of 15 patients with mantle cell lymphoma that has recurred or progressed following prior therapies.

Anticancer responses occurred in 33% of patients. After 13.4 months of follow-up, over half of the patients are still with us.

The researchers concluded that treatment with Velcade is effective for patients with mantle cell lymphoma that has stopped responding to prior therapies.

Proteosome inhibitor

Velcade is an agent referred to as a proteosome inhibitor. It interferes with the growth and survival of cancer cells responsible for some types of blood (hematologic) cancers. Velcade continues to be evaluated for the treatment of several types of cancers.

The most common severe side effects included side effects to the nerves, fatigue, and low levels of platelets.

Patients with mantle cell lymphoma may wish to speak with their physician regarding their individual risks and benefits of participating in a clinical trial further evaluating Velcade or other promising therapeutic approaches.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap